A patent-pending optical pre-scan technology calculates patient-specific radiation levels, aiming to improve workflow efficiency.
Izotropic Corp has integrated a new feature into its IzoView Breast CT Imaging System that uses a patent-pending optical pre-scan to deliver personalized radiation doses. The company announced that this capability makes the IzoView system the first in its category to offer real-time customized dosing.
The technology works by capturing a radiation-free optical image of the breast before the CT scan. Proprietary software then uses this pre-scan data to calculate a radiation dose tailored to the patient’s specific breast size and composition. This process is based on dose reference models developed at UC Davis Medical Center.
By automating dose calculation, the system is designed to streamline exam setup and enhance operational efficiency by removing the need for manual dose selection by a technician. The company states that this feature, combined with the system’s compression-free design, is intended to improve patient comfort and compliance.
The addition of patient-specific dosing aligns with a broader market trend toward personalized medicine. The global breast imaging market is projected to grow from $5.4 billion in 2024 to $8.69 billion by 2030, driven by factors including the adoption of technologies that support individualized imaging protocols and automation, according to the company.
IzoView is currently advancing through the US Food and Drug Administration’s Pre-Market Approval process. The company has achieved alignment with the agency on a clinical study design and is preparing to begin its pivotal US-based clinical study. Data from the first 100 patients in the US study will also be used for a European CE Mark submission as part of a dual-path strategy to accelerate market entry.
ID 58050063 © Supphachai Salaeman | Dreamstime.com
